Page 408 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(77) This is a fascinating and messy new area. The paper below gives
a good summary of the importance of analysing full trial programmes,
and the discrepancies found on Tamiflu between papers and Clinical Study
Reports: Jefferson T, Doshi P, Thompson M, Heneghan C, Group CARI. En-
suring safe and effective drugs: who can do what it takes? BMJ. 2011 Jan
11;342(jan11 1):c7258-c7258.

(78) This is all from: Jefferson T, Doshi P, Thompson M, Heneghan
C, Group CARI. Ensuring safe and effective drugs: who can do what it takes?
BMJ. 2011 Jan 11;342(jan11 1):c7258-c7258.

(79) Tom Jefferson, Lecture on Tamiflu, BMJ Evidence 2011, London.
(80) Doshi P, Jefferson T, Del Mar C (2012) The Imperative to Share
Clinical Study Reports: Recommendations from the Tamiflu Experience.
PLoS Med 9(4): e1001201. doi:10.1371/journal. pmed.1001201 http://bit
.ly/HIbwqO.
(81) Cohen D (2009) Complications: tracking down the data on os-
eltamivir. BMJ 339: b5387.
(82) If you’re interested in this story, the links to primary docu-
ments are all here: Diabetes drug ‘victory’ is really an ugly story about
incompetence. Ben Goldacre, The Guardian. 2010 Jul 17 [cited 2012
May 2]; Available from: http://www.badscience.net/2010/07/pharmaco-
epidemiology-would-be-fascinating-enough-even-if-society-didnt-
manage-it-really-really-badly/.
(83) Nissen SE. Setting the record straight. JAMA. 2010 Mar 24;
303(12):1194-5.
(84) Eichler H-G, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open
Clinical Trial Data for All? A View from Regulators. PLoS Med. 2012 Apr
10;9(4):e1001202.

408